Plant-cell-produced technologies-cutting edge approach to bringing solutions to the market
Science Conference: Innovations in Bioscience for Animal and Human HealthIndianapolis/Brussels: Four months after the world's first vaccine made in plant cells has received regulatory approval in the US, Dow AgroSciences is organising a Science Conference in Brussels on 7 June 2006 in order to share this knowledge with European researchers, scientists, decision-makers and industry representatives.
The pioneering vaccine developed by Dow AgroSciences works against the Newcastle disease virus (NDV) in poultry. The latest technology could be applied quite quickly to other diseases - with avian flu a prime target. This approval represents an innovative milestone for the company and the industry.
The Dow AgroSciences Concert Plant-Cell-Produced System represents a new category of plant-made vaccines. This leading edge technology utilises plant cells instead of whole plants in a secure, bio-contained environment to produce vaccines. Because of this bio-contained production system, concerns and challenges associated with making vaccines in whole plants or food crops are eliminated. The Concert Plant-Cell-Produced System uses only the necessary parts of the disease causing agent to stimulate immunity in a manufacturing process that is totally free of animal components: "Being the first company to ever register a plant-made vaccine is another example of Dow AgroSciences' cutting edge approach to bringing highly novel and differentiated solutions to the market," said Jerome Peribere, Dow AgroSciences' president and CEO.
The conference on 7 June, entitled "Innovations in Biosciences for Animal and Human Health" will highlight major bioscience developments and scientific solutions that could prevent diseases and reduce animal and human health risks in Europe. Dow AgroSciences President and Chief Executive Officer Mr. Jerome A. Peribere will deliver a welcome address. Dow AgroSciences's R&D capability will be presented by Mr. Antonio Galindez, (Dow AgroSciences Vice President, Europe, Latin America, Pacific) and Dr. Dan Kittle (Dow AgroSciences Vice President, Research and Development). Dr. Maurice Lex (European Commission, DG Research) will open discussion on Science Policy and R&D collaboration under the Seventh Framework Programme (FP7) in the area of biosciences for animal and human health.
Two parallel seminars will examine innovative plant-cell technologies and will present the benefit of healthy oils for consumers, agriculture and the food industry. The conference will also explore R&D collaboration under the EU's Seventh Framework Programme (FP7) in the area of biosciences for animal and human health.
Science Conference "Innovations in Bioscience for Animal and Human Health":
Date: 7 June 2006
Location: Renaissance Hotel, Rue du Parnasse 19, 1050 Brussels, Belgium
Online registration and the detailed programme is available at: http://www.isc-europe.com/dasconference/registration.php
For further information about the Dow AgroSciences Conference, please contact:
Rue Wiertz, 50/28
B-1050 Brussels, Belgium
Tel.: +32 (0)2 401 61 47
Fax: +32 (0)2 401 68 68
Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top tier agricultural company providing innovative crop protection, seeds, and biotechnology solutions to serve the world's growing population. A wholly owned subsidiary of The Dow Chemical Company, global sales for Dow AgroSciences are $3.4 billion. For further information on Dow AgroSciences, please visit: http://www.dowagro.com/homepage/index.htm
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.